Marliese Alexander
Overview
Explore the profile of Marliese Alexander including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
69
Citations
398
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Glewis S, Michael M, Gurney H, Olver I, Zdenkowski N, Ackland S, et al.
Br J Clin Pharmacol
. 2025 Feb;
PMID: 39988750
Aim: PREDICT-5FU aimed to document 5-fluorouracil (5FU) exposure in a cancer population and to evaluate the feasibility of 5FU and capecitabine therapeutic drug monitoring (TDM) in patients receiving standard doses...
2.
Shahnam A, Davis A, Brown L, Sullivan I, Lin K, Ng C, et al.
Lung Cancer
. 2025 Feb;
201:108421.
PMID: 39977966
Background: KRAS G12D and G12C mutations have distinct biological traits influencing treatment response. This study examines real-world demographics, clinical characteristics, and first-line treatment outcomes in metastatic non-small-cell lung cancer (NSCLC)...
3.
Dang T, Wickramasinghe N, Jayaraman P, Burbury K, Alexander M, Whitechurch A, et al.
JMIR Form Res
. 2025 Feb;
9:e65302.
PMID: 39969972
Background: Medication nonadherence is a serious problem in cancer, potentially impacts patients' health outcomes and health care costs. Although technology-based medication adherence (MA) interventions have emerged, evidence supporting their quality...
4.
Glewis S, Lingaratnam S, Lee B, Campbell I, IJzerman M, Fagery M, et al.
Clin Transl Sci
. 2024 Nov;
17(12):e70083.
PMID: 39614408
PACIFIC-PGx evaluated the feasibility of implementing pharmacogenetics (PGx) screening in Australia and the impact of DPYD/UGT1A1 genotype-guided dosing on severe fluoropyrimidine (FP) and irinotecan-related toxicities and hospitalizations, compared to historical...
5.
Dang T, Ludlow C, Borle H, Alexander M, Wickramasinghe N, Burbury K, et al.
PEC Innov
. 2024 Sep;
5:100335.
PMID: 39257627
Background: Oncology healthcare professionals (HCPs) using motivational interviewing may motivate and support patients with chronic illness to adhere to medications. Research of online motivational interviewing training focusing on medication adherence...
6.
Chazan G, Franchini F, Shah R, Alexander M, John A, IJzerman M, et al.
JTO Clin Res Rep
. 2024 Aug;
5(8):100662.
PMID: 39157676
Introduction: rearranged advanced NSCLC (aNSCLC) represents 4% of all NSCLCs, and multiple ALK-targeted therapies (ALK-inhibitors) are now available for use. Little is known about changes in treatment patterns, or how...
7.
Dang T, Wickramasinghe N, Jayaraman P, Burbury K, Alexander M, Whitechurch A, et al.
BMJ Open
. 2024 Jul;
14(7):e079122.
PMID: 39043598
Introduction: With the increasing use of oral anti-cancer medicines (OAMs), research demonstrating the magnitude of the medication non-adherence problem and its consequences on treatments' efficacy and toxicity is drawing more...
8.
Rafiq M, Drosdowsky A, Solomon B, Alexander M, Gibbs P, Wright G, et al.
Cancer Med
. 2024 Jul;
13(14):e70006.
PMID: 39001673
Introduction: Abnormal results in common blood tests may occur several months before lung cancer (LC) and colorectal cancer (CRC) diagnosis. Identifying early blood markers of cancer and distinct blood test...
9.
Wong A, Wang D, Gordon I, Alexander M, Siew B, Yap N, et al.
BMJ Support Palliat Care
. 2024 Jun;
PMID: 38918048
Objectives: Early opioid initiation is recommended for advanced cancer pain, however the timing of opioid commencement in relation to diagnosis has not been described, and the role of palliative care...
10.
Alexander M, Wolfe R, Burbury K
JAMA Oncol
. 2024 May;
10(7):989.
PMID: 38814615
No abstract available.